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Abstract
Introduction: The identification of specific targets for treatment of ovarian cancer patients remains a challenge. The
objective of this study is the analysis of oncogenic pathways in ovarian cancer and their relation with clinical outcome.
Methodology: A meta-analysis of 6 gene expression datasets was done for oncogenic pathway activation scores: AKT, b-
Catenin, BRCA, E2F1, EGFR, ER, HER2, INFa, INFc, MYC, p53, p63, PI3K, PR, RAS, SRC, STAT3, TNFa, and TGFb and VEGF-A.
Advanced serous papillary tumours from uniformly treated patients were selected (N=464) to find differences independent
from stage-, histology- and treatment biases. Survival and correlations with documented prognostic signatures (wound
healing response signature WHR/genomic grade index GGI/invasiveness gene signature IGS) were analysed.
Results: The GGI, WHR, IGS score were unexpectedly increased in chemosensitive versus chemoresistant patients. PR and
RAS activation score were associated with survival outcome (p=0.002;p=0.004). Increased activations of b-Catenin
(p=0.0009), E2F1 (p=0.005), PI3K (p=0.003) and p63 (p=0.05) were associated with more favourable clinical outcome and
were consistently correlated with three prognostic gene signatures.
Conclusions: Oncogenic pathway profiling of advanced serous ovarian tumours revealed that increased b-Catenin, E2F1,
p63, PI3K, PR and RAS –pathway activation scores were significantly associated with favourable clinical outcome. WHR, GGI
and IGS scores were unexpectedly increased in chemosensitive tumours. Earlier studies have shown that WHR, GGI and IGS
are strongly associated with proliferation and that high-proliferative ovarian tumours are more chemosensitive. These
findings may indicate opposite confounding of prognostic versus predictive factors when studying biomarkers in epithelial
ovarian cancer.
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Introduction
Epithelial ovarian cancer (EOC) is the most important cause of
mortality among gynaecological cancers. Patients with EOC often
present in an advanced stage. Treatment modalities consist in
general of the sequence of surgical cytoreduction and platinum-
taxane based chemotherapy [1]. Although the disease is relatively
sensitive to cytotoxics, relapse occurs in a majority of patients with
advanced stage [1]. The emergence of resistance to conventional
chemotherapeutics is an often-deadly event in the management of
ovarian cancer patients. There is an urgent need for additional
therapies that increase survival and/or quality of life in these
patients. Recent studies of VEGF-A inhibitors have shown
remarkable benefits [2–4]. Promising results have been reported
for PARP inhibitors in ovarian cancer patients with a BRCA1 or
BRCA2 mutation [5–7]. Individualization of therapy is necessary
since epithelial ovarian cancer is a heterogeneous disease. The
identification of specific targets for treatment remains a challenge.
Recent microarray technology and bioinformatics have shown
the ability of analysing oncogenic cellular signalling pathways
based upon gene signatures in cancers [8–10]. This may identify
cellular processes that may be targets to develop treatment
strategies. Survival can be used as a measure to quantify the
biological relevance in this disease. Ideally, evaluation of survival
outcome should be made in a homogenous population with a
uniform treatment to avoid treatment-induced biases and uniform
histology to find subtler differences independent from histology.
Therefore, in the present report, patients were selected by
including only patients with serous papillary histology, in advanced
stages (III/IV).
Another methodology of estimating prognostic value may be the
correlation with documented prognostic gene signatures that have
shown to be of prognostic value in breast cancer and other types of
cancer. The invasiveness gene signature (IGS) was generated using
stem cell-like or tumorigenic breast cancer cells [11]. This
signature has shown prognostic value in lung cancer, medullo-
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signature, based upon genes induced by wound healing, also has
shown its prognostic value in breast cancer, NSLC and bladder
cancer [12–14]. The genomic grade index (GGI) is a signature that
divides low-grade versus high-grade breast carcinomas [15].
Interestingly, using this signature, histological intermediate-grade
tumours could be classified as low- or high-grade tumours with the
preservation of the gene signatures’ prognostic value.
The objective of this study is the analysis of oncogenic pathways
in advanced serous papillary carcinoma through their relation with
survival outcome and correlation with known prognostic gene
signatures IGS/WHR/GGI.
Materials and Methods
Patient’s datasets
A dataset of 285 patients (Melbourne dataset) was obtained though
the Gene Expression Omnibus GEO database (GSE 9891) together
with the clinical annotation data file. Only patients that had
carcinomas of serous histology in advanced stages (III/IV) were
included for analysis. Patients were selected that received platinum
and taxane based chemotherapy. Other patients who did not receive
chemotherapy or received only one agent, platinum or taxane, were
also excluded. After this selection N=165 patients were eligible for
further analysis. This dataset contained gene expression data derived
from the Affymetrix U133_plus2 platform, which already underwent
normalisation using the Robust Multiarray Averaging (RMA)
method and subsequent filtering by excluding log expression values
of ,7 and a variance of ,0.5. After filtering there were 8,732 probe
sets left that are considered informative. Progression free survival was
used in further analysis [16].
A second dataset GSE3149 N=153 (North Carolina dataset) with
clinical data was also obtained from the GEO website. Here, the
same criteria for patient selection were used. After selection N=107
were further analysed. The North Carolina dataset used the same
Affymetrix U133_plus2 platform. The raw data were processed in
Bioconductor in R software packages. Filtering was done by selecting
expressions below a threshold (log 2 of 100) that are present in at least
25% of the arrayed samples. Normalisation was done using GC-
Robust Multiarray Averaging. The number of probe sets that were
informative was 7,741. Overall survival data was used, as there was
no progression free survival data available [8].
A third dataset (Que ´bec dataset) were patients (N=20) that
were selected to be either chemoresistant versus chemosensitive.
Here, raw microarray data based upon the Agilent platform
Human 1A (v2) oligonucleotide microarray were normalised using
the Lowess normalisation method. Hereafter, 16,096 genes were
eligible for further analysis. Progression free survival data were
used [17]. RAW gene expression data is publicly available
according to MIAME guidelines through the GEO database
(Accession number: GSE 28739) .
A fourth dataset (Niigata Dataset-GSE 17260) contained samples
that originated from patients who met the inclusion criteria from
present study. Progression free survival data were available. The
authors used the Agilent Whole Human Genome Oligo Microarray
platform and normalised the data using upper quartile normalisa-
tion. 28,446 genes were found to be informative [18].
A fifth and sixth dataset (Boston dataset A+B - GSE19829) were
derived from a report studying BRCAness in ovarian cancer [19].
Progression free survival data was used. After selection, (N=26)
and (N=36) patients were eligible. These datasets were RMA-
normalised. 35252 and 5626 probe set ID’s were informative after
filtering. Gene expression data was derived from two platforms:
the Affymetrix U133_plus2 platform and the Affymetrix 95UAv2.
Oncogenic and prognostic gene signatures
The oncogenic gene signatures were derived from a recent
paper by Gatza and colleagues [10] and applied similarly. Briefly,
for each array-sample the pathway-specific informative genes were
identified. Next a pathway score was calculated by adding up the
products of the gene expression for each gene and its
corresponding regression coefficient, which indicates the weight
(amplitude of regression coefficient) and the effect (sign of
regression coefficient) of the corresponding gene for activation of
the corresponding pathway. Finally, the pathway scores were
scaled using the intercept values provided in the original
manuscript and standardized for comparability by median-
centering and setting the standard deviation to 1. Pathways
included in the analysis were AKT, b-Catenin, E2F1, EGFR, ER,
HER2, INFa, INFc, MYC, p53, p63, PI3K, PR, RAS, SRC,
STAT3, TNFa, and TGFb.
A BRCA activation score was applied using the same
methodology with 60 genes, their weight and sign [19]. Prognostic
gene signatures (IGS, GGI and WHR) were also applied by
previously described methodology [11,12,15]. All gene signature
activation scores were handled as a continuous variable. The same
standardisation (Median=0; SD=1) was applied for each gene
signature.
VEGF-A activation gene signature
For the VEGF-A activation signature we used the 13 genes
reported by Hu and colleagues [20]. To validate and transform
this gene signature into a VEGF-A activation probability score we
performed subsequent analysis using publicly available gene
expression data sets on naı ¨ve and VEGF-A treated HUVEC cell
lines (GSE18913 (N=21), GSE10778 (N=9; only the HGU133A
samples were used) and GSE15464 (N=4)). Each data set was
normalised using the GC-RMA algorithm and informative genes
(above log 2(100) in at least 25% of the genes) were filtered in.
First, we applied a principal component analysis on the GSE18913
data set using the informative VEGF-A signatures genes only
(N=10). Significant segregation between the VEGF-A treated and
naı ¨ve cell lines was investigated using class label permutation.
Next, for these 10 genes, we used the regression coefficients that
define the first principal component to calculate the VEGF-A
activation probability score, in a similar way as described above.
The score was compared between VEGF-A treated and naı ¨ve
HUVEC’s using a Mann-Whitney U-test. To validate our
procedure, we applied our algorithm on the samples in gene
expression data sets GSE10778 and GSE15464.
Statistical analysis
Analysis of the gene signatures and array samples were done
using BioConductor in R. Correlations were calculated with the
Pearson correlation methods in SPSS 16.0 statistical software
packages. Standard errors for Pearson correlation coefficients were
estimated by the formula SE=(1-Rho‘2)/SQRT(n-1). Cox
proportional regression models estimated survival hazard ratios
with 95% confidence intervals. Meta-analysis was done using the
MIX 2.0 software using a random effects model for relative risk
and correlation coefficients.
Results
Generation of VEGF-A activation signature
The VEGF-A signature described by Hu and colleagues [20]
was derived from a matched analysis of primary tumours, lymph
node metastases and distant metastases in breast cancer. A 13-gene
profile, containing VEGF-A, discriminated between primary
Pathway Profiling in Ovarian Cancer
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distant metastases on the other hand. These 13 genes were
analysed on publicly available gene expression data sets of naı ¨ve
and VEGF-A treated HUVEC’s. First, the discriminative power of
the 13-gene signature to distinguish between VEGF-A treated and
naı ¨ve HUVEC’s was tested on gene expression data set
GSE18913. Within this data set, only 10 out of 13 genes (FABP5,
UCHL1, PLOD, DDIT4, VEGF, ADM, ANGPTL4, NDRG1, NP and
SLC16A3) were reliably measured (high signal-to-noise ratio).
Using these 10 genes in a principal component analysis (PCA) we
were able to demonstrate a significant segregation of VEGF-A
treated and naı ¨ve HUVEC’s along the first principal component.
Class label permutation analysis revealed that the observed
Euclidean distance between the centroids of the VEGF-A treated
and naı ¨ve HUVEC’s on the 2D scatterplot representation of the
PCA was significantly different from the expected Euclidean
distance (Figure 1A; Observed Euclidean distance=2.185,
Expected Euclidean distance=0.682, P,0.0001). Next, we
transformed the VEGF-A signature into a VEGF-A activation
probability score adopting the methodology described by Gatza
and his colleagues [10]. Therefore, we used the regression
coefficients that define the first principal component and
multiplied these with the gene expression values of their
corresponding genes. The products were summed and the
resulting score was compared between VEGF-A treated and naı ¨ve
HUVEC’s using a Mann-Whitney U-test (Median VEGF-A
Figure 1. A VEGF-A signature was able to distinguish VEGF treated and naı ¨ve HUVEC’s in the GSE18913 dataset. The 2D scatterplot of
the principal component analysis showed that the centroı ¨ds had an observed Euclidean distance different from the expected Euclidean distance
(p,0.0001). The first principal component of each sample is plotted along the X-axis, while the second principal component is plotted along the Y-
axis. VEGF-A treated HUVEC samples are represented in blue and VEGF-A untreated samples are represented in red. Centroı ¨ds of both conditions are
indicated by a black dot. (Panel A). After conversion to an activation score, the VEGF-A treated HUVEC’s showed higher VEGF-A activation score in a
time dependent relation (PANEL B AND C).
doi:10.1371/journal.pone.0022469.g001
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P,0.0001). The boxplot representation is provided in Figure 1B.
In addition, we observed a strong correlation between the VEGF-
A activation probability scores and the time of VEGF-A
incubation of HUVEC’s (Correlation coefficient=0.762;
P=0.038). (Figure 1C)
In order to validate our VEGF-A activation probability score,
we downloaded two more publicly available gene expression data
sets (GSE10778 and GSE15464) on VEGF-A treated and naı ¨ve
HUVEC’s. In the first data set (GSE10778), the median VEGF-A
activation probability score of the VEGF-A treated HUVEC’s
(N=4; Score=5.351) was significantly different from the score
observed in the naı ¨ve condition (N=1; Score=3.937)
(P=0.0209). A boxplot representation is provided in Figure 2A.
In addition, we observed a significant difference between the
VEGF-A treated (N=4; Score=5.351) and EGF-treated HU-
VEC’s (N=4; Score=4.307) (P=0.0431), suggesting that the
VEGF-A activation probability score is VEGF-A specific
(Figure 2B). Finally, we performed the same analysis for data set
GSE15464. In this case, we observed a trend towards a significant
difference between the VEGF-A treated HUVEC’s (N=3;
Score=4.069) and the score observed in the naı ¨ve condition
(N=1; Score=3.645) (P=0.0892). Again, a boxplot representa-
tion is provided in Figure 2C. In these two data sets, we observed
strong correlation coefficients between the VEGF-A incubation
time and the VEGF-A activation probability score (respectively
0.503 and 0.692), however the p-values did not reach significance,
probably due to the small sample sizes of the data sets.
Application of pathway activation signatures
We applied the oncogenic pathways on the six datasets. These
datasets together represent a total of N=464 advanced serous
papillary carcinomas. A summary of these 6 datasets is listed in
Table 1. Since these are selected oncogenic pathways, it is
plausible that many significant correlations were found between
pathway activations and the 3 prognostic signatures (IGS, WHR
and GGI). The b-Catenin pathway showed consistent and strong
correlations. (Table 2) Since the six datasets were generated on
different platforms with different methodologies, we estimated the
overall effect of a pathway activation score by using a meta-
analysis approach (Table 2). Similar meta-analysis of correlation
coefficients showed that the BRCA, E2F1, EGFR, HER2, MYC,
p53, p63 and PI3K showed steady correlations with the WHR,
GGI and IGS. The RAS pathway and TGFb pathway showed
significant correlations with 2/3 prognostic signatures. Table 3
shows the overall correlation estimates, which were the most
significant. While most pathway activation scores showed a
positive correlation, the EGFR, HER2, p53 and TGFb pathway
showed a negative correlation.
Survival Analysis
Next, we looked at clinical outcome and the degree of pathway
activation. While some pathways were associated with survival
outcome in one or more datasets, they showed no or opposite
result in another dataset. To estimate the overall survival effect of a
given pathway, a similar meta-analysis approach was performed to
estimate the overall effect of pathway activation using a random
effects model. After this analysis, the b-Catenin, E2F1, PR, p63
PI3K and RAS pathway activation showed a significant
association with clinical outcome. Considering the overall effect
by means of Hazard Ratios, the b-Catenin pathway showed the
most prominent effect after meta-analysis (HR=0.74; 95%CI
[0.62–0.88]). The survival analysis showed that the higher the
activation of the b-Catenin pathway, the better the outcome was.
Also for PR, E2F1, RAS, PI3K and p63 increased activation of
respective pathway was associated with more favourable survival.
(Figure 3)
Because of these rather unexpected results, we calculated the
activation scores of selected discovered pathways in other
independent datasets as additional quality control to confirm
whether the directions of the activation scores were certainly
correct. For b-Catenin the activation scores were found to be
higher (borderline significance, p=0.06) in paediatric medullo-
blastoma with a CNTBB1 mutation (N=4) versus non-mutated
medulloblastomas [21]. For the RAS activation score, K-RAS
mutated colorectal cancers (N=27) had a significant higher
activation score (p=0.03) than wild type cancers (N=43) [22].
PIK3CA-mutated cancers (N=14) had a higher -although non
significant- PI3K activation score (p=0.11) than non-mutated
breast cancers (N=29) [23]. The PR activation scores were higher
(p=0.06) in ER positive, PR positive breast cancers (N=59)
versus ER positive, PR negative breast cancers (N=18) [24].
For the 3 prognostic signatures there was a tendency that a
prognostic worse outcome predicted by IGS, WHR and GGI
Figure 2. Validation of the VEGF-A activation score was performed in dataset GSE10778 (PANEL A) and GSE15464 (PANEL C). In
both datasets, activation scores of VEGF-A treated HUVEC’s (boxplots) were higher than the untreated condition (red dots). For GSE 10778, there was
a higher activation score in VEGF-A treated cells, but not in EGF treated cells. (PANEL B).
doi:10.1371/journal.pone.0022469.g002
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outcome. Further analysis in the Que ´bec dataset showed that
chemoresistant patients showed significant lower scores than
chemosensitive patients and therefore may explain this finding.
(WHR p=0.02; GGI p=0.002; IGS p=0.06) (Figure 4)
Discussion
Although VEGF-A inhibition has proven to be active in ovarian
cancer, the VEGF-A activation signature we studied did not prove
to be of any significant prognostic value in this meta-analysis. A
number of considerations must be made: First, it may not be
necessary that VEGF-A biology automatically would be of any
prognostic value, even if VEGF-A inhibition has demonstrated to
be effective [2,3]. Secondly, although this signature was validated
on gene expression data and was able to distinguish between
VEGF-A treated versus untreated HUVEC’s cells, it may lack the
ability in clinical samples.
Table 1. A summary of datasets that were used in the meta-analysis.
Dataset N=464 Platform Normalisation
Clinical
outcome
Uniform
treatment
Advanced stage/
serous papillary
histology Remarks
Que ´bec 2006 20 Agilent Human 1A (v2) Lowess PFS yes yes patients were selected either to be
chemosensitive versus chemosensitive
North Carolina 2006 107 Affymetrix U133_plus2 GC-RMA OS yes yes
Melbourne 2008 165 Affymetrix U133_plus2 RMA PFS yes yes
Niigata 2010 110 Agilent Whole Human
Genome Oligo Microarray
Upper quartile PFS yes yes
Boston A 2010 26 Affymetrix U133_plus2 RMA PFS yes yes all patients were BRCA1&2 mutation
negative
Boston B 2010 36 Affymetrix U95_A2 RMA PFS yes yes dataset enriched for BRCA1&2
mutation negative patients/patients
with no relevant family history of
ovarian/breast cancer
doi:10.1371/journal.pone.0022469.t001
Table 2. Table 2 shows the consistent correlations of the b-
Catenin activation scores and WHR/IGS/GGI in each separate
dataset (Que ´bec, North Carolina, Melbourne, Niigata, Boston
A and Boston B dataset).
Pearson Rho WHR IGS GGI
Que ´bec 0.65 0.62 0.67
p=3.4 E-4 p=0.001 p=2.0 E-4
North Carol 0.81 0.89 0.6
p=7.7 E-40 p=9.9 E-59 p=8.0 E-18
Melbourne 0.73 0.54 0.79
p=2.8 E-22 p=6.9 E-11 p=5.6 E-28
Niigata 0.77 0.73 0.79
p=2.4 E-19 1.0 E-22 p=4.5 E-25
Boston A 0.83 0.48 0.87
p=1.2 E-7 p=0.013 p=5.5 E-9
Boston B 0.75 0.56 0.26
p=1.8 E-7 p=3.7 E-4 p=0.13
Meta Analysis 0.73 0.62 0.79
p,0.0001 p,0.0001 p,0.0001
Overall Rho Coefficients were estimated by a meta-analysis approach using
random models effects.
doi:10.1371/journal.pone.0022469.t002
Table 3. Estimates of Pearson rho correlation coefficients
after meta-analysis of six datasets between pathway
activation scores and prognostic gene signatures: wound
healing response signature (WHR)/Invasiveness gene
signature IGS and Genomic grade Index (GGI).
Rho estimates WHR IGS GGI
b-Catenin 0.73 0.62 0.79
p,0.0001 p,0.0001 p,0.0001
BRCA 0.43 0.36 0.36
p,0.0001 p,0.0001 p,0.0001
E2F1 0.51 0.42 0.54
p,0.0001 p,0.0001 p,0.0001
EGFR 20.52 20.43 20.42
p,0.0001 p,0.0001 p,0.0001
HER2 20.45 20.5 20.26
p,0.0001 p,0.0001 p,0.0001
MYC 0.69 0.53 0.4
p,0.0001 p,0.0001 p,0.0001
p53 20.59 20.42 20.72
p,0.0001 p,0.0001 p,0.0001
p63 0.46 0.29 0.36
p,0.0001 p=0.001 p,0.0001
PI3K 0.43 0.33 0.29
p,0.0001 p,0.0001 p=0.002
RAS 0.51 0.2 0.4
p,0.0001 p=0.017 p,0.0001
TGFb 20.23 20.3 20.13
p=0.0001 p,0.0001 p=0.004
Most significant correlations are shown. (Threshold p-value adjusted for
multiple testing=0.0025).
doi:10.1371/journal.pone.0022469.t003
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mutated vs sporadic disease was able to divide a population of
sporadic epithelial ovarian cancers in tumours with a ‘‘BRCAness-
like’’ and a ‘’non-BRCA-like’’ profile. These two groups had
significant different clinical outcome in terms of overall and
progression free survival. In the present meta-analysis this BRCA-
profile was correlated with prognostic signatures, however it did
not prove to be of significant prognostic/predictive value
considering the total of 6 datasets. The difference in patient
selection may partly account for this finding. Konstantinopoulos
and colleagues selected patients enriched for sporadic cancers,
which were predominantly BRCA1 and BRCA2 mutation
negative [19]. Here, patients were selected for advanced stages,
serous papillary histology and uniform chemotherapy regimen.
Furthermore, we did not use a cut-off point to divide patients in
BRCA-like and non-BRCA-like tumours. Since our objectives
were to find biological associations, rather than to validate a
specific biomarker in the perspective for possible clinical usage, we
used the BRCA-activation score as a continuous variable in
survival and correlation analysis.
Our initial analysis consisted of two datasets. The initial design
was to use one dataset, as a discovery dataset while the other one
would serve as a validation set. Since bioinformatical mislabelling
errors/reproducibility issues have lead to withdrawal of papers of
the same research group from which one dataset originated, we
sought additional datasets to confirm our findings and render
more power and reliability [25–27]. Furthermore, this research
group and critical review by another research group have
confirmed that the dataset that was used in the present meta-
analysis was indeed correctly annotated [9,28]. With the
availability of more datasets, we noticed variation among
pathway’s association with survival outcome. We therefore used
a meta-analysis approach to estimate the overall effect. The
advantage is that several studies can be combined despite
differences in platforms and methodologies. This overall effect
estimation takes into account the number of patients of each
separate dataset and confidence interval in the estimation of
correlation coefficient of survival hazard ratios. The heterogeneity
among datasets (e.g. different patient selection criteria) may partly
explain some opposite findings. The Que ´bec dataset is different
from others because this specifically selected patients to study
differential expression between chemosensitive versus chemoresis-
tant tumours [17]. This dataset therefore may represent the
extremities of this disease. Interestingly this dataset showed clearly
that chemosensitive patients had tumours that were more likely to
be of unfavourable outcome estimated by WHR/IGS/GGI. This
contradictory finding may be explained by the finding that these
three prognostic signatures are all primarily associated with
increased proliferation [29]. It is known that chemosensitive
tumours have higher tumour cell proliferation indexes in serous
ovarian cancer [30,31]. The estimated prognostic values in this
survival analysis therefore seems strongly oppositely confounded
by the predictive value for platinum/taxane-based chemotherapy.
Despite the heterogeneity in datasets and confounding of
predictive value versus prognostic value, the E2F1, b-Catenin
and the PI3K activation scores showed overall association with
survival outcome (p,0.01) and consistent significant correlations
with three prognostic signatures. (Table 3+Figure 5)
The E2F1 pathway a critical role in proliferation and apoptosis.
It has been shown that transcription factor E2F1 interacts with the
p53 and PI3K pathway [32–34]. Its role in ovarian cancer has
been unclear, as other research groups have found similar
favourable survival with increased E2F1 pathway activation [32],
while other findings have shown favourable survival with
decreased E2F1 gene expression by RT-PCR [33,34]. It must be
remarked that the latter study included an overrepresentation of
patients with clear cell carcinomas (42.9%) and may be less
informative here.
The b-Catenin protein is a multifunctional protein. It was
originally discovered as a protein that is associated with the
cytoplasmatic region of E-cadherin. E-cadherin is a transmem-
brane protein that is involved in cell-cell contact and cell’s
adhesive functions. Furthermore, b-Catenin is involved in Wnt
signalling as a nuclear transcription factor and is believed to play a
Figure 3. Forest plots of meta-analysis using a random effects model of the b-Catenin BRCA, E2F1, p63, PR, PI3K, RAS and VEGF
pathway. The VEGF and BRCA signature was overall not significantly associated with clinical outcome. The other pathways showed significant
association with survival after meta-analysis using 6 datasets (Que ´bec, North Carolina, Melbourne, Niigata, Boston A, Boston B). Note the larger 95%
Confidence intervals of the Que ´bec dataset due to lower number of patients. Along the X-axis, hazard ratios are indicated by the centre of each
square for each dataset. The meta-analysis used a weighted method (shown by the size of the squares/and the percentages indicated for each
dataset) based upon confidence interval/number of patients. The 95% confidence interval for each hazard ratio is indicated by the width of the blue
lines originating from the squares. The vertical red line shows the overall hazard ratio after meta-analysis, with the width of the diamond as the 95%
confidence interval.
doi:10.1371/journal.pone.0022469.g003
Figure 4. In the Que ´bec dataset sensitive (S) patients showed a higher genomic grade index (GGI) compared to chemoresistant
patients (R) (p=0.002). Similarly chemosensitive patients showed a higher wound healing response score (p=0.02) and a higher invasiveness
gene signature score (IGS) (p=0.06).
doi:10.1371/journal.pone.0022469.g004
Pathway Profiling in Ovarian Cancer
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higher nuclear presence has been linked with poor survival in
several studies in ovarian cancer based upon immunohistochem-
ical studies [36–40]. In addition, a correlation of b-Catenin
protein expression has been described with tumour grade and Ki-
67 expression [39,40]. Present results are thus confirmative of
earlier findings that b-Catenin is associated with survival outcome.
The consideration must be made whether this effect is not
attributed to its predictive value to platinum-taxane chemotherapy
rather than its prognostic value. In present study, b-Catenin had
strong and consistent correlation with IGS/WHR/GGI. Although
these signatures were constructed based upon different oncogenic
biological processes (wound healing, stem cell phenotype, grade),
their major common force has been proven to be cell proliferation
[29]. The observation that chemosensitive patients in present
analysis showed significantly higher values of GGI, WHR and IGS
renders credibility to this statement.
Similarly, the unexpected findings that increased activation of
PI3K-, and RAS- pathways are more favourable for survival may be
explained by their predictive value for chemotherapy. This
hypothetically may have clinical consequences. Several compounds
target the PI3K pathway or downstream effectors (e.g. mTOR) and
are under early clinical development in epithelial ovarian cancer.
Other compounds have inhibitory effects on the RAS pathway, e.g
lonafarnib (a farnesyltransferase inhibitor). Recent findings of a
randomised phase II trial (IGCS meeting 2010, W. Meier et al.)
showed that the concomitant addition to standard chemotherapy
(first line) and 6-month continuation of lonafarnib in primary
epithelial ovarian cancer stage IIB-IV (n=105) resulted in borderline
pooreroutcomefortheexperimental-lonafarnibarm(overallsurvival
HR=0.62 95CI%(0.36–1.06) p=0.08) or even resulted insignificant
unexpected worse outcome (p=0.01) in the experimental stratum of
patients with suboptimal debulking. This finding may be relevant in
the context of our results. Since increased activation of pathways as
RAS and PI3K have been found to be favourable for survival
outcome, the question should be asked whether inhibition of one of
these pathways concomitant with chemotherapy is desirable. These
pathways are driving forces of proliferation, which is an important
factor in the efficacy of standard chemotherapeutics. We hypothesize
that inhibition of these pathways may therefore also negatively affect
the efficacy of these chemotherapies and theoretically induce
chemoresistance. This would possibly be an explanation for the
recent unexpected findings of lonafarnib in ovarian cancer. Hence,
we theorize that these agents may have their potential in ovarian
cancer in a sequential adjuvant setting rather than its concomitant
combination with chemotherapy.
The PR pathway did not show any relevant association with IGS
or GGI. It did show high significant association with survival
outcome and WHR. Other immunohistochemical studies have
shown that the PR protein expression has predictive of prognostic
value, more than the expression of ER [41–44], Since PR
expression is a downstream target of the ER pathway, this finding
may indicate that an active ER pathway, rather than the expression
of ER by itself may be of importance. Anti-hormonal therapies have
shown anti-tumoural activity in relapsed/refractory ovarian cancer
in phase II studies [45–49]. Biomarker studies have shown that
increasing ER expression was associated with increasing CA125
response rate [47]. We suggest that further studies are needed to
study if PR expression may add value as a suitable biomarker to
select patients for anti-hormonal therapy in ovarian cancer.
To conclude, oncogenic pathway profiling of advanced serous
ovarian tumours revealed that it is difficult to estimate the true
prognostic value of a pathway since there seems confounding of
predictive factors. Despite these biases, with a meta-analysis
approach of 6 independent datasets generated on different micro-
array platforms, we found that a PR and a RASactivation scorewas
associated with clinical outcome. Activation scores for b-Catenin,
p63, E2F1 and PI3K were also associated with survival and were
consistently correlated with three prognostic gene signatures.
Further studies are needed to elucidate whether these pathways
may help in designing targeted therapies treatment strategies.
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Figure 5. A Venn diagram is showing combined results of the meta-analysis: b-Catenin, E2F1, p63 and PI3K activation scores
showed significant association with survival and were significantly correlated with all three prognostic signatures (WHR/IGS/GGI)
after meta-analysis. PR and RAS activation scores were associated with clinical outcome, but did not consistently correlate with prognostic
signatures. *Negative correlation coefficient **borderline significance with clinical outcome.
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